Kalvista Pharmaceuticals Inc (KALV) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $15.76
• Market Cap: $796.61M
• EPS: $-3.94
• 52-Week High: $19.00
• 52-Week Low: $9.23

Market Sentiment

Kalvista Pharmaceuticals Inc currently has a Bullish sentiment score of 0.45.

About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative small-molecule protease inhibitors for unmet medical conditions. The company focuses on therapeutic areas such as hereditary angioedema and diabetic macular edema, utilizing its proprietary drug development platform to create targeted treatments. With a strong pipeline of candidates and strategic partnerships, KalVista is well-positioned to m...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Kalvista Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KALV pay dividends?

Kalvista Pharmaceuticals Inc (KALV) does not currently pay a regular dividend.

What is KALV's market cap?

Kalvista Pharmaceuticals Inc (KALV) has a market capitalization of $796.61M with a current stock price of $15.76.